All lobbying filings
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Lobbying for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$190,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Texas
Government bodies contacted
5
Lobbying activity
3
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act